Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.69 USD | -3.46% | -1.00% | +33.54% |
Financials (USD)
Sales 2024 * | 98.05M | Sales 2025 * | 83.06M | Capitalization | 85.31M |
---|---|---|---|---|---|
Net income 2024 * | -94M | Net income 2025 * | -48M | EV / Sales 2024 * | 0.39 x |
Net cash position 2024 * | 47.51M | Net cash position 2025 * | 57.37M | EV / Sales 2025 * | 0.34 x |
P/E ratio 2024 * |
-0.9
x | P/E ratio 2025 * |
-2.06
x | Employees | 225 |
Yield 2024 * |
280% | Yield 2025 * |
280% | Free-Float | 94.1% |
Latest transcript on Atara Biotherapeutics, Inc.
1 day | -0.54% | ||
1 week | -0.03% | ||
Current month | +2.98% | ||
1 month | +2.48% | ||
3 months | +23.14% | ||
6 months | -46.26% | ||
Current year | +39.37% |
Managers | Title | Age | Since |
---|---|---|---|
Pascal Touchon
CEO | Chief Executive Officer | 61 | 19-06-23 |
Eric Hyllengren
DFI | Director of Finance/CFO | - | 17-12-31 |
Anhco Nguyen
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-05-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Gallagher
CHM | Chairman | 59 | 12-12-31 |
Eric Dobmeier
BRD | Director/Board Member | 55 | 15-03-25 |
William Heiden
BRD | Director/Board Member | 64 | 15-11-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.03% | 509 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 0.6848 | -4.19% | 247 498 |
24-04-24 | 0.7147 | -0.54% | 697,941 |
24-04-23 | 0.7186 | +3.04% | 833,904 |
24-04-22 | 0.6974 | +5.51% | 856,889 |
24-04-19 | 0.661 | -4.44% | 1,626,286 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.37% | 85.31M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.86% | 22.2B | |
-16.53% | 21.23B | |
-8.49% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- ATRA Stock